Citation: | HU Bingxue, DONG Xue, FAN Hongwei, ZHU Yongqiang, ZHANG Yin, ZHANG Zhao. Cardiotoxicity evaluation of three novel proteasome inhibitors in zebrafish[J]. Journal of China Pharmaceutical University, 2019, 50(4): 452-458. DOI: 10.11665/j.issn.1000-5048.20190410 |
[1] |
Liang JF,Jin WD,Li HW,et al.In vivo cardiotoxicity induced by sodium aescinate in zebrafish larvae[J].Molecules,2016,21(3):190.
|
[2] |
Kantae V,Krekels EH,Ordas A,et al.Pharmacokinetic modeling of paracetamol uptake and clearance in zebrafish larvae:expanding the allometric scale in vertebrates with five orders of magnitude[J].Zebrafish,2016,13(6):504-510.
|
[3] |
Macrae CA,Peterson RT.Zebrafish as tools for drug discovery[J].Nat Rev Drug Discov,2015,14(10):721-731.
|
[4] |
Wang CM,Wei YJ,Jia XB.Evaluation of antiosteoporotic activity for micro-amount asperosaponins v and vi by on the osteoporosis model using zebrafish[J].J China Pharm Univ(中国药科大学学报),2014,45(1):88-91.
|
[5] |
Brown DR,Clark BW,Garner LV,et al.Zebrafish cardiotoxicity:the effects of CYP1A inhibition and AHR2 knockdown following exposure to weak aryl hydrocarbon receptor agonists[J].Environ Sci Pollut Res Int,2015,22(11):8329-8338.
|
[6] |
Simoneschi D,Simoneschi F,Todd NE.Assessment of cardiotoxicity and effects of malathion on the early development of zebrafish(danio rerio)using computer vision for heart rate quantification[J].Zebrafish,2014,11(3):275-280.
|
[7] |
Li MM,Wang XJ,Zhu JG,et al.Toxic effects of polychlorinated biphenyls on cardiac development in zebrafish[J].Mol Biol Rep,2014,41(12):7973-7983.
|
[8] |
Vargas RA.Effects of GABA,neural regulation,and intrinsic cardiac factors on heart rate variability in zebrafish larvae[J].Zebrafish,2017,14(2):106-117.
|
[9] |
Cornet C, Calzolari S, Miñana-Prieto R, et al. ZeGlobalTox:an innovative approach to address organ drug toxicity using zebrafish[J].Int J Mol Sci,2017,18(4):E864.
|
[10] |
Saley A,Hess M,Miller K,et al.Cardiac toxicity of triclosan in developing zebrafish[J].Zebrafish,2016,13(5):399-404.
|
[11] |
Honton B,Despas F,Dumonteil N,et al.Bortezomib and heart failure:case-report and review of the French Pharmacovigilance database[J].Fundam Clin Pharmacol,2014,28(3):349-352.
|
[12] |
Hasinoff BB,Patel D,Wu X.Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib[J].Cardiovasc Toxicol,2017,17(3):237-250.
|
[13] |
Jouni H,Aubry MC,Lacy MQ,et al.Ixazomib cardiotoxicity:a possible class effect of proteasome inhibitors[J].Am J Hematol,2017,92(2):220-221.
|
[14] |
Manasanch EE,Orlowski RZ.Proteasome inhibitors in cancer therapy[J].Nat Rev Clin Oncol,2017,14(7):417-433.
|
[15] |
Gilda JE,Gomes AV.Proteasome dysfunction in cardiomyopathies[J].J Physiol(Lond),2017,595(12):4051-4071.
|
[16] |
Barac YD,Emrich F,Krutzwakd-Josefson E,et al.The ubiquitin-proteasome system:a potential therapeutic target for heart failure[J].J Heart Lung Transplant,2017,36(7):708-714.
|
[17] |
Food and Drug Administration HHS.International conference on harmonisation;guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization(QT interval prolongation)by human pharmaceuticals;availability.notice[J].Fed Regist,2005,70(202):61133-61134.
|
[18] |
Food and Drug Administration,HHS.International conference on Harmonisation;guidance on S7A safety pharmacology studies for human pharmaceuticals;availability.Notice[J].Fed Regist,2001,66(135):36791-36792.
|
[19] |
Genge CE,Lin E,Lee L,et al.The zebrafish heart as a model of mammalian cardiac function[J].Rev Physiol Biochem Pharmacol,2016,171:99-136.
|
[20] |
Zakaria ZZ,Benslimane FM,Nasrallah GK,et al.Using zebrafish for investigating the molecular mechanisms of drug-induced cardiotoxicity[J].Biomed Res Int,2018,2018:164284.
|
[21] |
Milan DJ,Peterson TA,Ruskin JN,et al.Drugs that induce repolarization abnormalities cause bradycardia in zebrafish[J].Circulation,2003,107(10):1355-1358.
|
[1] | SHANG Feiyang, LIU Chengbo, TAN Hongzhou, HE Bing, HE Liqin. Design, synthesis and antiplatelet aggregation activity of 3-acetyl-7-hydroxycoumarin derivatives[J]. Journal of China Pharmaceutical University, 2024, 55(3): 367-374. DOI: 10.11665/j.issn.1000-5048.2023072901 |
[2] | HU Yuheng, SUN Jie, YANG Jie, WANG Xiaojing. Synthesis and in vitro hypoglycemic activity of 3-(4′-benzoyl amino-phenyl)-coumarin derivatives[J]. Journal of China Pharmaceutical University, 2019, 50(2): 168-174. DOI: 10.11665/j.issn.1000-5048.20190206 |
[3] | YANG Guoxun, XIONG Juan, HU Jinfeng. 2017′s advanced natural products chemistry researches in China(2)[J]. Journal of China Pharmaceutical University, 2018, 49(6): 637-645. DOI: 10.11665/j.issn.1000-5048.20180601 |
[4] | YANG Guoxun, XIONG Juan, HU Jinfeng. 2017′s advanced natural products chemistry researches in China(1)[J]. Journal of China Pharmaceutical University, 2018, 49(5): 511-520. DOI: 10.11665/j.issn.1000-5048.20180501 |
[5] | YANG Rui, ZHU Yi, WANG Yin, MA Wenqi, WANG Xin, HAN Xiqiong, LIU Naifeng. Recent progress in autophagy and vascular calcification[J]. Journal of China Pharmaceutical University, 2018, 49(4): 401-406. DOI: 10.11665/j.issn.1000-5048.20180403 |
[6] | JIN Yue, WU Xuri, CHEN Yijun. Applications of glycosyltransferases in the improvement of druggability of natural products[J]. Journal of China Pharmaceutical University, 2017, 48(5): 529-535. DOI: 10.11665/j.issn.1000-5048.20170504 |
[7] | YU Sulan, YU Xiu, KOU Junping. Advances in the mechanism research of natural products against acute lung injury[J]. Journal of China Pharmaceutical University, 2016, 47(4): 397-403. DOI: 10.11665/j.issn.1000-5048.20160403 |
[8] | XIANG Min, ZHANG Yaqin, WU Pingping, GAO Zhenyu. Effect of block of AGEs-RAGE pathway on the migration of VSMCs[J]. Journal of China Pharmaceutical University, 2016, 47(2): 199-203. DOI: 10.11665/j.issn.1000-5048.20160212 |
[10] | YANG Ya-Bo, WANG Min, LIANG Yan, LIANG Jing-Yu. Transgalactosylation of Isotaxiresinol by[J]. Journal of China Pharmaceutical University, 2002, (6). |